Trial Profile

Phase II Study of Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer or Those With Progression on First Line Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
Indications Neuroendocrine tumours; Small cell lung cancer
Focus Therapeutic Use

Most Recent Events

25 Jul 2025 Status changed from active, no longer recruiting to completed.
12 Jul 2023 Primary endpoint has been changed to overall Response Rate, Patients will be evaluated every 2 cycles until progression or off treatment (up to 3 years).
04 Jun 2021 Planned End Date changed from 1 Apr 2024 to 1 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com